Immunogenicity of CAR T cells in cancer therapy DL Wagner, E Fritsche, MA Pulsipher, N Ahmed, M Hamieh, M Hegde, ... Nature reviews Clinical oncology 18 (6), 379-393, 2021 | 176 | 2021 |
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion L Amini, SK Silbert, SL Maude, LJ Nastoupil, CA Ramos, RJ Brentjens, ... Nature Reviews Clinical Oncology 19 (5), 342-355, 2022 | 164 | 2022 |
Concise review: a comprehensive analysis of reported adverse events in patients receiving unproven stem cell-based interventions G Bauer, M Elsallab, M Abou-El-Enein Stem cells translational medicine 7 (9), 676-685, 2018 | 152 | 2018 |
Overcoming challenges facing advanced therapies in the EU market M Abou-El-Enein, A Elsanhoury, P Reinke Cell Stem Cell 19 (3), 293-297, 2016 | 152 | 2016 |
Regulatory T cells for minimising immune suppression in kidney transplantation: phase I/IIa clinical trial A Roemhild, NM Otto, G Moll, M Abou-el-Enein, D Kaiser, G Bold, ... bmj 371, 2020 | 143 | 2020 |
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours CL Flugel, RG Majzner, G Krenciute, G Dotti, SR Riddell, DL Wagner, ... Nature Reviews Clinical Oncology 20 (1), 49-62, 2023 | 131 | 2023 |
Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy M Abou-el-Enein, M Elsallab, SA Feldman, AD Fesnak, HE Heslop, ... Blood cancer discovery 2 (5), 408-422, 2021 | 130 | 2021 |
Toward an optimized process for clinical manufacturing of CAR-Treg cell therapy E Fritsche, HD Volk, P Reinke, M Abou-El-Enein Trends in biotechnology 38 (10), 1099-1112, 2020 | 86 | 2020 |
Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs M Abou-El-Enein, A Römhild, D Kaiser, C Beier, G Bauer, HD Volk, ... Cytotherapy 15 (3), 362-383, 2013 | 82 | 2013 |
CAR T-cell product performance in haematological malignancies before and after marketing authorisation M Elsallab, BL Levine, AS Wayne, M Abou-El-Enein The Lancet Oncology 21 (2), e104-e116, 2020 | 70 | 2020 |
Telbivudine in chronic lymphocytic myocarditis and human parvovirus B19 transcriptional activity S Van Linthout, A Elsanhoury, O Klein, M Sosnowski, K Miteva, D Lassner, ... ESC heart failure 5 (5), 818-829, 2018 | 42 | 2018 |
Putting a price tag on novel autologous cellular therapies M Abou-El-Enein, G Bauer, N Medcalf, HD Volk, P Reinke Cytotherapy 18 (8), 1056-1061, 2016 | 42 | 2016 |
Mitigating Deficiencies in Evidence during Regulatory Assessments of Advanced Therapies: A Comparative Study with Other Biologicals M Elsallab, CA Bravery, A Kurtz, M Abou-El-Enein Molecular Therapy. Methods & Clinical Development 18, 269, 2020 | 40 | 2020 |
COVID-19-induced ARDS is associated with decreased frequency of activated memory/effector T cells expressing CD11a++ M Anft, K Paniskaki, A Blazquez-Navarro, A Doevelaar, FS Seibert, ... Molecular Therapy 28 (12), 2691-2702, 2020 | 39 | 2020 |
Cell and gene therapy trials: are we facing an ‘evidence crisis’? M Abou-El-Enein, SP Hey EClinicalMedicine 7, 13-14, 2019 | 36 | 2019 |
Strategies for derisking translational processes for biomedical technologies M Abou-El-Enein, GN Duda, EA Gruskin, DW Grainger Trends in biotechnology 35 (2), 100-108, 2017 | 36 | 2017 |
The business case for cell and gene therapies M Abou-El-Enein, G Bauer, P Reinke Nature biotechnology 32 (12), 1192-1193, 2014 | 36 | 2014 |
Human genome editing in the clinic: new challenges in regulatory benefit-risk assessment M Abou-El-Enein, T Cathomen, Z Ivics, CH June, M Renner, ... Cell Stem Cell 21 (4), 427-430, 2017 | 34 | 2017 |
The human genome editing race: loosening regulatory standards for commercial advantage? T Cathomen, S Schüle, M Schüßler-Lenz, M Abou-El-Enein Trends in biotechnology 37 (2), 120-123, 2019 | 30 | 2019 |
Registry contributions to strengthen cell and gene therapeutic evidence M Abou-El-Enein, DW Grainger, S Kili Molecular Therapy 26 (5), 1172-1176, 2018 | 29 | 2018 |